Unravelling molecular and cellular liaison between immune system and cancer cells is gaining tremendous momentum across the globe. The gamut of genetics and epigenetics changes occurring in tumors provides diverse set of antigenic repertoire that host’s immune system can exploit to distinguish tumour versus their normal healthy counterparts. Intriguingly, an insight in their conceptual and technical footing paves the way to discover innovative cancer immunotherapy modes. Of late the area of cancer immunotherapies has been the subject of rigorous investigations and likely to hold the forefront of cancer therapy. There is in general consensus that cytotoxic T cells (CTLs) play cardinal role in antitumor immunity. However, accumulating evidence both from clinical and animal studies advocates that activation of the CTL immune effector arm alone is inadequate to mediate effective anticancer immunity. This has led a paradigm shift from activation of CTL immunity alone to activation of T helper cell immune response alone or in harmony with CTL to impart protective antitumor immunity. Furthermore, recently it has been increasingly recognized that cancer cells recruit Treg cells to inhibit antitumor immunity and have great implications in limiting the efficacy of the immunotherapeutic strategies; thus inhibition/depletion of Treg cells is entailed for harnessing the benefits of immunotherapies.

We invite researchers to contribute their original research articles as well as literature reviews to accelerate progressing efforts to explore potential of the immune system to turn the tide against this dreadful disease. We are interested in articles that explore facet of antitumor immunity and their application to immunotherapeutic strategies for the benefit of the cancer clientele.

Potential topics include, but are not limited to:

• Identification of biomarkers of protective immunity against cancer
• Illuminating the role of host factors in the development of antitumor immunity
• Elucidation and characterization of tumor antigens as potential contenders in cancer prophylaxis or as potential targets in cancer immunotherapy
• Strategies exploited to stimulate effector Th cells and inhibit Treg cells to achieve effective antitumor immunity
• Recent developments in immunotherapeutic strategies with special convergence on prophylactic/therapeutic vaccines and combinatorial therapeutic approaches
• Clinical investigations with relevance to tumor immunology and immunotherapies